Christian Angermayer, the chairman of Germany-based biopharmaceutical company atai Life Sciences (ATAI) announced today that the firm would develop its own bitcoin treasury strategy.



“In an era of persistent inflation and volatile markets, I find myself asking an important question for biotech companies looking to preserve and optimize the capital they have: Could allocating a portion of treasury cash to bitcoin help preserve, optimize, and even extend a company’s runway and hence contribute to its success,” Angermayer wrote on Substack.

The company will initially invest $5 million in bitcoin, Angermayer said, while holding enough cash, short-term securities and public equity for operational expenses into 2027.
#TUT Price Rise
#Crypto ETFs Under Application
OWN0.00%
BTC0.32%
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
7377 views
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned